Thelansis

Carcinoid Syndrome (CS) Market Outlook Thelansis’s “Carcinoid Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Carcinoid Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

Carcinoid Syndrome (CS) Market Outlook Thelansis’s “Carcinoid Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Carcinoid Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Carcinoid Syndrome (CS) Overview Carcinoid syndrome (CS) is a paraneoplastic syndrome caused by the discharge of serotonin and different substances from well-differentiated neuroendocrine tumors (NETs). CS is a paraneoplastic syndrome associated with the secretion of around 40 vasoactive hormones, the majority of which are 5-hydroxytryptamine (5-HT). CS also involves the secretion of histamine (primary gastric NETs), prostaglandins E ...

Carcinoid syndrome (CS) is a paraneoplastic syndrome caused by the discharge of serotonin and different substances from well-differentiated neuroendocrine tumors (NETs). CS is a paraneoplastic syndrome associated with the secretion of around 40 vasoactive hormones, the majority of which are 5-hydroxytryptamine (5-HT). CS also involves the secretion of histamine (primary gastric NETs), prostaglandins E and F, kallikrein, and tachykinins. The hallmark symptoms of carcinoid syndrome are diarrhea and flushing; atypical signs and symptoms can include wheezing, pellagra, valvular heart disease, telangiectasias, abdominal pain, and the complications of mesenteric fibrosis, including ureteral obstruction, bowel ischemia, and bowel obstruction. These symptoms are mediated by the release of serotonin (5-HT), prostaglandins, kallikrein, histamine, and tachykinins. These symptoms, as well as the corresponding elevations in lab tests, are required for the diagnosis of CS. Surgery and medical manage...